ViroCell Biologics ("ViroCell" or the "Company"), a specialist viral vector Contract Development and Manufacturing ...

UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia ViroCell Biologics ...

Professor Amrolia selected ViroCell to manufacture the lentiviral vector for this novel CAR T-cell therapy based on its track record for delivering high quality vector. Through this relationship ...

ProBio, a global contract development and manufacturing organization (CDMO), announced that it will present six poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, 'P134 Cell Injection,' which has received Investigational New Drug (IND) ...

Q4 2024 Earnings Conference Call April 9, 2025 8:00 AM ET. Company Participants. Frank Mathias - Chief Executive Officer Sebastien Ribault - Chi ...

researchers used a lentiviral vector to deliver gene therapy to five patients with hemophilia A. After treatment, all five had stable levels of factor VIII in their blood, with no serious safety ...